AZN250117P56000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have received FDA priority review status for their antibody-drug conjugate datopotamab deruxtecan.
Datopotamab deruxtecan has previously been granted breakthrough therapy designation by the FDA for this patient population.
AstraZeneca (AZN) Receives a Buy From Barclays
AstraZeneca's Dato-DXd BLA Accepted for Priority Review
Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
FDA Grants Priority Review to Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan for Advanced Lung Cancer Treatment
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
AstraZeneca's Promising Pipeline and Strategic Initiatives Drive Buy Recommendation
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
AstraZeneca Hits 9-week High
Astra, Merck Drugs Set to Shake Up Liver Cancer Treatment
Why Astrazeneca (AZN) Is a Top Growth Stock for the Long-Term
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
AstraZeneca (AZN) Gets a Buy From TD Cowen
BOCOM INTL: Maintains Hutchmed (China) 'Buy' rating, Target Price raised to 44 HKD.
BOCOM INTL released a research report stating that it maintains a "Buy" rating for Hutchmed (China) (00013), believing that the transaction conditions are reasonable and favorable for the company's long-term development. The earnings forecast has been adjusted, and the DCF Target Price has been raised to 44 Hong Kong dollars. The company has made continuous key progress in the development of pipelines in the mid to late stage, with relevant catalysts to look forward to in 2025, including: 1) Based on the success of the SAVANNAH study, partner AstraZeneca will soon submit the first overseas NDA for Savolitinib to the FDA (2/3 LMET abnormal treatment-resistant NSCLC); 2) China Phase III SACHI study.
J&J Lung Cancer Treatment Extends Lives Versus AstraZeneca Drug | NYSE:JNJ
Unusual Options Activity: BP, TPR and Others Attract Market Bets, BP V/OI Ratio Reaches 156.3
EST Jan 7th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC